ALX Oncology Holdings Inc. Common Stock earnings per share and revenue
On 07 de nov. de 2025, ALXO reported earnings of -0.41 USD per share (EPS) for Q3 25, missing the estimate of -0.37 USD, resulting in a -9.63% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +16.95% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -0.36 USD, with revenue projected to reach -- USD, implying an diminuir of -12.20% EPS, and aumentar of 0.00% in Revenue from the last quarter.
FAQ
What were ALX Oncology Holdings Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ALX Oncology Holdings Inc. Common Stock reported EPS of -$0.41, missing estimates by -9.63%, and revenue of $0.00, 0% as expectations.
How did the market react to ALX Oncology Holdings Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 16.95%, changed from $1.18 before the earnings release to $1.38 the day after.
When is ALX Oncology Holdings Inc. Common Stock expected to report next?
The next earning report is scheduled for 04 de mar. de 2026.
What are the forecasts for ALX Oncology Holdings Inc. Common Stock's next earnings report?
Based on 6
analistas, ALX Oncology Holdings Inc. Common Stock is expected to report EPS of -$0.36 and revenue of -- for Q4 2025.